Valuation: Prothena Corporation plc

Market Cap 475M 408M 383M 349M 659M 45.29B 663M 4.53B 1.75B 22.85B 1.78B 1.74B 75.68B P/E 2026 *
84.1x
P/E 2027 * -9.95x
Enterprise Value 475M 408M 383M 349M 659M 45.29B 663M 4.53B 1.75B 22.85B 1.78B 1.74B 75.68B EV / Sales 2026 *
5.71x
EV / Sales 2027 * 19.5x
Free-Float
78.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.80%
1 week-0.43%
Current month+13.92%
1 month+5.71%
3 months-8.05%
6 months+7.06%
Current year-3.14%
1 week 9.09
Extreme 9.09
9.82
1 month 8
Extreme 8
9.82
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
56.63
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Tech/Sci/R&D Officer 53 01/01/2015
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
8/20/26 A Buy 50,000 0.0955%
8/18/26 A Don -627,553 1.1987%
8/10/26 A Don 251,553 0.4805%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-0.43%+10.78%-82.78% 475M
+3.31%-3.70%+61.03%+103.64% 70.42B
+0.49%+1.90%+48.45%+92.08% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.20%+2.03%+59.48%+11.93% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
+0.09%+0.33%+36.86%-16.09% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+2.59%+0.28%+15.34%+555.83% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.36%+1.00%+54.92%+170.53% 28.88B
Weighted average by Cap. +0.98%+0.72%+56.39%+157.74%

Financials

2026 *2027 *
Net sales 83.16M 71.37M 66.99M 61.18M 115M 7.93B 116M 793M 307M 4B 312M 305M 13.25B 24.38M 20.92M 19.64M 17.93M 33.85M 2.32B 34.01M 232M 90.06M 1.17B 91.52M 89.53M 3.88B
Net income 6.22M 5.34M 5.01M 4.58M 8.64M 594M 8.68M 59.34M 23M 299M 23.37M 22.86M 992M -49.57M -42.55M -39.94M -36.48M -68.84M -4.73B -69.17M -473M -183M -2.39B -186M -182M -7.9B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
26/08/26 $9.250 -1.80% 289,040
25/08/26 $9.420 +0.32% 363,713
24/08/26 $9.390 -0.63% 248,124
21/08/26 $9.450 +4.65% 376,044
20/08/26 $9.030 -2.80% 345,968
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.250USD
Average target price
21.40USD
Spread / Average Target
+131.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock